Acorda Therapeutics is developing treatment options for people suffering from neurological disorders and Acorda.com offers information about their products, research, and careers with the company. Resources for patients on Acorda.com include their patient assistance programs, community programs, and links to advocacy organizations for patients of neurological conditions and MS. Assistance programs from Acorda include full or partial reimbursement for their Ampyra and Zanaflex capsule medications for patients who qualify.
Some of the products developed by Acorda include Ampyra, Zanaflex, AC105, GGF2, rHlgM22, and Chondroitinase. Ampyra has been demonstrated to help increase walking speed of patients with MS. Zanaflex Capsules (tizanidine hydrochloride) are indicated for spasticity management for MS patients as well as those people who has suffered from a spinal cord injury, stroke, or brain spasms. AC105 has been developed by Acorda for the acute treatment of spinal cord injuries with potential applications for stoke and traumatic brain injury. GGF2 may be used for stimulating repair in cardiac and nervous systems with additional potential applications for MS, spinal cord injuries, strokes, and peripheral nerve repair. The rHlgM22 product is a Remyelinating Monoclonal Antibody and Acorda.com states that it has potential applications for the treatment of MS. This product has been developed in collaboration with the Mayo Foundation for Medical Education and Research. Lastly, Chondroitinase is listed on acorda.com for potential applications in the treatment of spinal cord injuries for improving motor and sensory function.
The Career section on Acorda.com includes a list of current job openings with the company in the fields of marketing, communications, clinical operations, and research and development. Information about working at Acorda, including benefits is also provided on Acorda.com as well as an online application for interested individuals. 
